Clinical trials: Neovascularization, Choroidal
Polypoidal Choroidal Vasculopathy, Choroidal Neovascularization
Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV
The purpose of the present study was to evaluate the outcomes of type 1 macular neovascularization (MNV), including polypoidal choroidal vasculopathy in patients treated tolerating subretinal fluid (SRF) using Aflibercept in a…
- Conditions
- Polypoidal Choroidal Vasculopathy, Choroidal Neovascularization, Age-Related Macular Degeneration
- Trial name
- NCT05662943
- Testing
- Intravitreal aflibercept injection
- Where
- South Korea
- Volunteers
- 135 people
- Sponsor
- Kim's Eye Hospital
Age-Related Macular Degeneration, Choroidal Neovascularization
Retinal Therapy Guided by 3D OCT Image Analysis
The main purpose is to find a better way to predict the timing of treatments given to patients with Wet Age-related macular degeneration using image analysis.
- Trial name
- NCT02308215
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Michael Abramoff
Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD
Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)
To evaluate and compare two individualised ranibizumab treatment regimens, differentiated by the definition of disease activity, which determines the treatment interval until the next injection.
- Trial name
- FLUID (NCT01972789)
- Testing
- Ranibizumab
- Where
- 16 sites in Australia
- Volunteers
- 349 people
- Sponsor
- Novartis Pharmaceuticals
Macular Degeneration Choroidal Neovascularization
Deep Learning Optical Coherence Tomography (OCT) and OCT Angiography (OCTA) in NVC
To evaluate the activity of neovascular macula degeneretion as assessed by SD-OCTand OCT-A using a split-person study design and deep-learning quantification.
- Trial name
- OCTA (NCT05969418)
- Testing
- Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter
- Where
- Italy
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Federico II University
Wet Macular Degeneration
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with…
- Trial name
- NCT03823287
- Testing
- Faricimab, Aflibercept
- Where
- 161 sites in United States, Canada and 13 more
- Volunteers
- 671 people
- Sponsor
- Hoffmann-La Roche
Polypoidal Choroidal Vasculopathy
Aqueous Humor Level of Cytokines in Polypoidal Choroidal Vasculopathy and Change of Cytokines After Photodynamic Therapy
This is a prospective, comparative control analysis. The investigators want to evaluate the aqueous humor levels of vascular endothelial growth factor in polypoidal choroidal vasculopathy and the effect of photodynamic therapy…
- Trial name
- NCT01360151
- Testing
- ranibizumab(Lucentis), verteporfin(Visudyne)
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Seoul St. Mary's Hospital
Uveitis, Diabetic Retinopathy
Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot Study
Direct intravitreal administration of medication is the preferred method of treatment for uveitis and retinal vascular disorders.
- Conditions
- Uveitis, Diabetic Retinopathy, Choroidal Neovascularization
- Trial name
- ADA01 (NCT00855608)
- Testing
- adalimumab
- Where
- Lebanon
- Volunteers
- 15 people
- Sponsor
- Rafic Hariri University Hospital
Choroidal Neovascularization, Degenerative Myopia
Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular Degeneration (AMD)
The purpose of this study is to see if the drug bevacizumab is safe and effective to use for people with choroidal neovascularization (CNV).
- Conditions
- Choroidal Neovascularization, Degenerative Myopia, Pathological Myopia
- Trial name
- NCT00407719
- Testing
- Bevacizumab
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Age Related Macular Degeneration
Combination Therapy for Age-Related Macular Degeneration.
The primary purpose of the study is to investigate whether patients with Choroidal Neovascularization secondary to Age-related Macular Degeneration, receiving triple or double therapy compared to monotherapy with Avastin will…
- Trial name
- NCT00376701
- Testing
- Avastin (Bevacizumab), Bevacizumab
- Where
- 5 sites in Canada
- Volunteers
- 103 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Choroidal Neovascularization, Age-Related Maculopathy
Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)
The study will evaluate the safety and efficacy of the intravitreal dexamethasone implant as adjunctive therapy to Anti-VEGF treatment in the study eye of treatment naïve subjects with choroidal neovascularization secondary to…
- Trial name
- NCT00775411
- Testing
- dexamethasone, ranibizumab
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 44 people
- Sponsor
- Allergan
Age Related Macular Degeneration
Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients
The purpose of the study is to provide efficacy and safety data for monthly ranibizumab 0.5 mg intravitreal injections in Chinese patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular…
- Trial name
- EXTEND II (NCT00826371)
- Testing
- ranibizumab 0.5 mg
- Where
- 6 sites in China
- Volunteers
- 114 people
- Sponsor
- Novartis Pharmaceuticals
Wet Macular Degeneration
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with…
- Trial name
- NCT03823300
- Testing
- Faricimab, Aflibercept
- Where
- 137 sites in United States, Argentina and 19 more
- Volunteers
- 658 people
- Sponsor
- Hoffmann-La Roche
Choroidal Neovascularization
Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
The purpose of study is to determine if Lucentis combined with imatinib mesylate will help treatment in patients with newly diagnosed choroidal neovascularization.
- Trial name
- NCT00403156
- Testing
- Imatinib Mesylate /Ranibizumab
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Vitreous -Retina- Macula Consultants of New York
Age-Related Macular Degeneration, Choroidal Neovascularization
Stratus Versus Cirrus OCT in AMD
The Cirrus OCT provides due to the spectral domain technology a 2-fold resolution than Stratus OCT generated in a comparable amount of time.
- Trial name
- NCT00568191
- Where
- Austria
- Volunteers
- 100 people
- Sponsor
- The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Choroidal Neovascularization
Bevacizumab Effect on Blood Velocity
Retinal blood flow velocity is affected by Bevacizump intravitreal injection. This effect is correlated to treatment success.
- Trial name
- NCT01298440
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Optical Imaging, Ltd.
Choroidal Neo-Vascular Age-onset Macular Degeneration, Age-related Macular Degeneration
The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration
The study will assess the safety and efficacy of Everolimus (RAD001) alone or in combination with Lucentis in patients with neo-vascular age related macular degeneration (AMD)
- Trial name
- NCT00857259
- Testing
- Everolimus, Ranibizumab
- Where
- 12 sites in United States, United Kingdom
- Volunteers
- 16 people
- Sponsor
- Novartis Pharmaceuticals
Exudative Macular Degeneration, Wet Age-related Macular Degeneration
MMP-9 Inhibition for Recalcitrant Wet AMD
Wet (or neovascular) form of age-related macular degeneration (wAMD) is the most common cause of blindness in the Western world.
- Trial name
- NCT04504123
- Testing
- Doxycycline Hyclate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Iowa
Macular Degeneration, Choroidal Neovascularization
Evaluation of Dosing Interval of Higher Doses of Ranibizumab
Evaluation of Dosing Interval of Higher Doses of Ranibizumab for patients with wet age-related macular degeneration (AMD).
- Trial name
- BGB/IST (NCT00533520)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Brandon G. Busbee, MD
PCV, Polypoidal Choroidal Vasculopathy
Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)
This is a 24-month study of ranibizumab (2.0 mg and 1.0 mg) in subjects with polypoidal choroidal vasculopathy as diagnosed by fluorescein/indocyanine green (FA/ICG) angiography.
- Trial name
- PEARL2 (NCT01884597)
- Testing
- high-dose ranibizumab, ranibizumab
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Hawaii Pacific Health
Wet Age-related Macular Degeneration
A Study to Evaluate the Neovista Ophthalmic System for the Treatment of Subfoveal CNV in Patients With AMD That Have Failed Primary Anti-VEGF Therapy
The objective of this clinical study is to evaluate the safety and feasibility of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) in patients with age related macular degeneration…
- Trial name
- ROSE (NCT00679445)
- Testing
- NeoVista Ophthalmic System
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- NeoVista